Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients

Study on the Brain Hippocampal Volume, Cortisol and C-reactive Protein Levels Relationship With Anxious Symptoms in Major Depressive Patients

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04430556

Enrollment

Registered

2020-06-12

Start date

2018-07-01

Completion date

2020-12-31

Last updated

2020-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Major Depressive Disorder

Keywords

major depressive disorder, hippocampal volume, cortisol, c-reactive protein, brain metabolites, MRI, anxiety

Brief summary

The objective of this transversal study is to determine if there is a difference in the volume of the hippocampus with the degree of anxiety.

Interventions

DRUGSertraline

Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* First-time patients, without prior antidepressant treatment that meet the diagnostic criteria of DSM 5 for major depressive disorder. * Patients who meet the current major depressive disorder criteria in the MINI interview. * Patients who signed the informed consent for the investigation.

Exclusion criteria

* Patients presenting insufficient data in the MINI interview for current major depression. * Patients diagnosed with intellectual development disorder, by clinic. * Patients with diagnosis of the schizophrenic spectrum, bipolar disorder, autism spectrum disorder, post-traumatic stress disorder and obsessive-compulsive disorder by clinic and / or by the MINI interview. * Patients with contraindications for MRI. * Patients with serious or unstable medical problems. * Patients undergoing some legal procedure. * Patients with difficulties in understanding the interview or completing the assessment instruments.

Design outcomes

Primary

Measure	Time frame	Description
Response on Hamilton Anxiety Rating Scale	Change from baseline to week 8	The Hamilton Anxiety Rating Scale and its correlation with hippocampal size

Secondary

Measure	Time frame	Description
Response on Hamilton Depression Rating Scale	Change from baseline to week 8	Difference between baseline and final score
Response on Montgomery-Asberg Scale for Depression	Change from baseline to week 8	Difference between baseline and final score
Response on Columbia Scale for Suicidality	Change from baseline to week 8	Difference between baseline and final score
Response on Clinical Global Impression-Improvement	Change from baseline to week 8	Difference between baseline and final score
Response on Beck Anxiety Inventory	Change from baseline to week 8	Difference between baseline and final score
Response on EQ-5D	Change from baseline to week 8	Difference between baseline and final score
Response on State-Trait Depression Inventory	Change from baseline to week 8	Difference between baseline and final score

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026